PMID- 38398014
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240227
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 12
IP  - 2
DP  - 2024 Feb 9
TI  - Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic 
      Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center 
      Retrospective Study.
LID - 10.3390/biomedicines12020413 [doi]
LID - 413
AB  - Cabozantinib, an oral inhibitor targeting MET, AXL, and VEGF receptors, has 
      become a key component of a sequential treatment strategy for clear cell renal 
      cell carcinoma (ccRCC). The purpose of this work is to show that effective 
      management of adverse events (AEs) during cabozantinib treatment and achieving a 
      balance between AEs and treatment efficacy is crucial to achieving therapeutic 
      goals. In this retrospective study, involving seventy-one metastatic RCC (mRCC) 
      patients receiving second or subsequent lines of cabozantinib at the Department 
      of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of 
      Oncology, we explored the impact of AEs on overall survival (OS) and 
      progression-free survival (PFS). AEs were observed in 92% of patients. 
      Hypothyroidism during treatment was significantly associated with prolonged OS 
      and PFS (HR: 0.31; p < 0.001 and HR: 0.34; p < 0.001, respectively). The 
      occurrence of hand-foot syndrome (HFS) was also linked to improved OS (HR: 0.46; 
      p = 0.021). Patients experiencing multiple AEs demonstrated superior OS and PFS 
      compared to those with one or no AEs (HR: 0.36; p < 0.001 and HR: 0.30; p < 
      0.001, respectively). Hypothyroidism and HFS serve as valuable predictive factors 
      during cabozantinib treatment in ccRCC patients, indicating a more favorable 
      prognosis.
FAU - Domanski, Piotr
AU  - Domanski P
AUID- ORCID: 0009-0003-2205-4093
AD  - Department of Experimental Immunotherapy, Maria Sklodowska-Curie National 
      Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
AD  - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research 
      Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
FAU - Pietak, Mateusz
AU  - Pietak M
AUID- ORCID: 0000-0001-6451-1238
AD  - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research 
      Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
FAU - Kruczyk, Barbara
AU  - Kruczyk B
AUID- ORCID: 0009-0001-5782-7151
AD  - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research 
      Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
FAU - Jarosinska, Jadwiga
AU  - Jarosinska J
AD  - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research 
      Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
FAU - Mydlak, Anna
AU  - Mydlak A
AD  - Department of Head and Neck Oncology, Maria Sklodowska-Curie National Research 
      Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
FAU - Demkow, Tomasz
AU  - Demkow T
AD  - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research 
      Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
FAU - Darewicz, Marta
AU  - Darewicz M
AD  - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research 
      Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
FAU - Sikora-Kupis, Bozena
AU  - Sikora-Kupis B
AD  - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research 
      Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
FAU - Dumnicka, Paulina
AU  - Dumnicka P
AUID- ORCID: 0000-0003-3667-857X
AD  - Department of Medical Diagnostics, Jagiellonian University Medical College, 
      31-008 Cracow, Poland.
FAU - Kamzol, Wojciech
AU  - Kamzol W
AD  - Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of 
      Oncology, Roentgena 5, 02-781 Warsaw, Poland.
FAU - Kucharz, Jakub
AU  - Kucharz J
AUID- ORCID: 0000-0001-5388-8910
AD  - Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research 
      Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
LA  - eng
PT  - Journal Article
DEP - 20240209
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC10886567
OTO - NOTNLM
OT  - adverse events
OT  - cabozantinib
OT  - metastatic renal cell carcinoma (mRCC)
OT  - predictive factor
OT  - tyrosine kinase inhibitors (TKI)
COIS- Honoraria: Angelini, Astellas, Astra Zeneca, Bayer, Bristol Myers Squibb, IPSEN, 
      Janssen, Merck MSD, Novartis, Pfizer, Research Funding: Novartis. All unrelated 
      to the present paper.
EDAT- 2024/02/24 11:45
MHDA- 2024/02/24 11:46
PMCR- 2024/02/09
CRDT- 2024/02/24 01:10
PHST- 2024/01/07 00:00 [received]
PHST- 2024/01/22 00:00 [revised]
PHST- 2024/02/06 00:00 [accepted]
PHST- 2024/02/24 11:46 [medline]
PHST- 2024/02/24 11:45 [pubmed]
PHST- 2024/02/24 01:10 [entrez]
PHST- 2024/02/09 00:00 [pmc-release]
AID - biomedicines12020413 [pii]
AID - biomedicines-12-00413 [pii]
AID - 10.3390/biomedicines12020413 [doi]
PST - epublish
SO  - Biomedicines. 2024 Feb 9;12(2):413. doi: 10.3390/biomedicines12020413.